Abstract
Objective
The aim of study is to investigate whether hematological inflammatory biomarkers could be useful to detect patients with lung cancer.
Methods
The contribution of hematological biomarkers to the diagnosis of lung cancer and prediction of TNM was examined.
Results
NLR, PLR, MPV values were found to be higher in patients with lung cancer (all p < .001). NLR and PLR were found to be high, MPV was found to be lower in disease of advanced stage (p < .001).
Conclusions
This study found that NLR, PLR and MPV values were significantly higher in patients with lung cancer.
Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.